- Design
- Prespecified analysis of a phase 3, randomised, placebo-controlled trial
- Population
- 238 adults with generalised AChR+ or MuSK+ myasthenia gravis
- Primary outcome
- Exacerbations, including crisis and rescue therapy
- Effect
- HR 0.41 (95% CI 0.24–0.70) at 26 weeks; AChR+ HR 0.39 at 52 weeks
A prespecified analysis of the phase 3 MINT trial in JAMA Neurology (1 October) looked at exacerbations in 238 adults with generalised myasthenia gravis, either AChR or MuSK antibody-positive, randomised to inebilizumab or placebo while all tapered prednisolone to 5 mg a day or less.
Exacerbations — crisis, a defined worsening of daily-living scores, or rescue with immunoglobulin or plasma exchange — were reduced by about 60% over 26 weeks (hazard ratio 0.41). The effect held at 52 weeks in AChR-positive patients (HR 0.39) and appeared larger in the small MuSK-positive group (HR 0.21).
The steroid taper is where many patients relapse, so a drug that protects through it addresses a real clinical problem. This is a secondary analysis of one trial; long-term safety of B-cell depletion and access remain the practical constraints.
- Exacerbations and rescue therapy were reduced by about 60% during the steroid taper
- Benefit was seen in both AChR- and MuSK-positive generalised disease
- B-cell depletion carries infection risk; check hepatitis B and immunoglobulins before starting
- Regulatory status and access in India are not established here
Why it matters
The steroid taper is the point at which many patients flare and need rescue therapy.
Don't overread it
A secondary analysis — the MuSK result rests on a small subgroup with a wide confidence interval.
The statistics, in plain English
A hazard ratio of 0.41 (95% CI 0.24 to 0.70) means the risk of an exacerbation at any given time was well under half that on placebo. The MuSK estimate of 0.21 (0.06 to 0.79) is striking but imprecise because the subgroup was small.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free